# A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

> **NCT01594723** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 110 (estimated)

## Conditions studied

- Neoplasms, Hematologic

## Interventions

- **DRUG:** 120 mg LY2784544

## Key facts

- **NCT ID:** NCT01594723
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-05-22
- **Primary completion:** 2015-03-20
- **Final completion:** 2026-12
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01594723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01594723, "A Study of LY2784544 in Participants With Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01594723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*